(Date:5/16/2008)... - Speakers include industry and customer...wire/ -- Velos, Inc., the recognized,leader and tr...ms this week,hosted a constellation of prestigious...nd industry partners at its annual user group meet...llows customers to internally and,collaboratively ...
(Date:5/16/2008)... Highlights Include:, -- Results demonstratin... a clinically meaningful extension of progression-...tuzumab to attack both the inside and,outside of t...lockade, -- Data demonstrating activity of TYKERB...ultiple lines of trastuzumab and chemotherapy, LO...
(Date:5/16/2008)... RARITAN, N.J., May 16 /- Veridex...tor, Laboratory Corporation of America Holdings,(L...ylation test for,prostate cancer. The new assay us... in prostate cancer, detecting the methylation of ...DNA that occurs primarily in,cancer. Veridex is de...
(Date:5/15/2008)... - Trial Results Confirm Efficacy for Population ...VILLE, Calif., May 16 /-,Ba...maceuticals, Inc.,(Nasdaq: ONXX ) today announced... improved overall survival by 47.3 percent (HR=0.6...region with advanced,hepatocellular carcinoma (HCC...
Breaking Medicine Technology:Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Do migratory birds see the magnetic field 3F 564 1Gentiva 28R 29 Health Services Files Universal Shelf Registration Statement 2045 1Gentiva 28R 29 Health Services Files Universal Shelf Registration Statement 2045 2Gentiva 28R 29 Health Services Files Universal Shelf Registration Statement 2045 3International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in 827 1International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in 827 2Study expected to boost research for hearing and balance therapies 2042 1Study expected to boost research for hearing and balance therapies 2042 2...0, 2007 - Valeant,Pharmaceuticals International (N...2 data for retigabine, a first-in-class,neuronal p...ndependent, scientific journal. The authors conclu...rated reduction in monthly,seizure rates in this s...TORE2) are currently underway to further investiga...
...2007 - The two most,prevalent forms of genetic men... share a common cause, according to researchers at...em, a crippled,communication network in the brain,... genetics of the disorders are very different, the...id Daniel Madison,PhD, associate professor of mol...
Other Medicine Technology:Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4(Date:5/16/2008)...ointment of Nomura Code Securities Limited as ...NEW YORK, May 16 /PRNewswire-FirstCall/ -- Medicsi...Inc. (Amex: MGT ) (the "Company"), and an,industr...ction (CAD) and,image analysis software which assi...e, today announced the appointment of NM Rothschil...
(Date:5/16/2008)...PRNewswire/ -- Barbara Senich, B.S.N., M.B.A.,M.P...vices, was honored by,Executive Women of New Jerse... Awards Dinner. The biennial event, held May 15, 2... women of professional distinction in New,Jersey w...irectors at major,New Jersey-based corporations an...
(Date:5/16/2008)... /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmace...C) ("Genesis" or,the "Company"), a leading pharmac... today announced that it had donated medicines wit...S$428,000) to Sichuan Earthquake relief.,These med...008 Beijing,Time., "We are extremely grieved to k...
(Date:5/16/2008)...ty and efficacy of first FDA-approved nebulized ... severe COPD -, NAPA, Calif., May 16 /PRNewswire/...data presentations will be given at the Internatio...TS) on May 20, 2008 at the,Metro Toronto Conventio...ects on dyspnea and other COPD symptoms of using P...
Breaking Medicine News(10 mins):Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Roche Vice President Senich Honored at EWNJ 'Salute to Policy Makers' 2Health News:Roche Vice President Senich Honored at EWNJ 'Salute to Policy Makers' 3Health News:Genesis Pharmaceuticals Donates Medicine to China Sichuan Earthquake Relief 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 3Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 4Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 5...r may delay your chances of getting treated// for ...he British Journal of Cancer, valuable time is los...nosis gets delayed. Patients with suspected prosta...es later than those with breast cancer patients wh...
...hed the association between adult urinary incontin...more than 1000 Turkish women, the research says th... the same for exhibiting lack of control in contro...rs feel that these women may suffer from some faul...
...first direct association of faulty metabolism with...rallels from an animal study. Atherosclerosis or c... substances, cholesterol, cellular waste products,...r lining of the arteries. This build up is called ...
...tsburgh had said in a new study that there’s adequ...ith age, in spite of the elderly frequenting the b...dder capacity and stability, urethral closure pres...ontraction strength from 95 females of ages 22 to ...
Other Medicine News:... Novametrix' family of capnography products. Along...handheld, mainstream capnographs available today, ...rway condition and ventilatory status. Based on th...iniaturized the size, not the performance. TIDAL W...
The Models 512 and 513 handheld pulse oximeters incorporate "digital signal processing. This advanced technology is able to process pulsatile signals at much higher resolutions and speeds of 100 time
...ulse Oximeter is a one-of-a-kind oximeter that off...tion of the N-20PA has been shock-tested, vibratio... conditions it has even withstood the rigors of M... check measurements and also useful for continuous...
...er with Oxismart XL Advanced Signal Processing rea...through nonspecific noise to find the pulse and tr... N395 monitor is also equipped with SatSeconds Ala...mable alarm sensitivity for pulse oximetry. SatSec...
Medicine Products: